Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.

Jansson KH, Tucker JB, Stahl LE, Simmons JK, Fuller C, Beshiri ML, Agarwal S, Fang L, Hynes PG, Alilin AN, Lake R, Abbey YC, Cawley J, Tice CM, Yin J, McKnight C, Klummp-Thomas C, Zhang X, Guha R, Hoover S, Simpson RM, Nguyen HM, Corey E, Thomas CJ, Proia DA, Kelly K.

Sci Rep. 2018 Nov 22;8(1):17239. doi: 10.1038/s41598-018-35417-0.

2.

Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors.

London CA, Acquaviva J, Smith DL, Sequeira M, Ogawa LS, Gardner HL, Bernabe LF, Bear MD, Bechtel SA, Proia DA.

Clin Cancer Res. 2018 Dec 15;24(24):6396-6407. doi: 10.1158/1078-0432.CCR-18-0703. Epub 2018 Aug 31.

3.

Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD).

Nikonova AS, Deneka AY, Kiseleva AA, Korobeynikov V, Gaponova A, Serebriiskii IG, Kopp MC, Hensley HH, Seeger-Nukpezah TN, Somlo S, Proia DA, Golemis EA.

FASEB J. 2018 May;32(5):2735-2746. doi: 10.1096/fj.201700909R. Epub 2018 Jan 10.

4.

Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation.

Wang Y, Liu H, Diao L, Potter A, Zhang J, Qiao Y, Wang J, Proia DA, Tailor R, Komaki R, Lin SH.

Clin Cancer Res. 2016 Dec 1;22(23):5876-5886. Epub 2016 Jun 28.

5.

Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.

Bobrov E, Skobeleva N, Restifo D, Beglyarova N, Cai KQ, Handorf E, Campbell K, Proia DA, Khazak V, Golemis EA, Astsaturov I.

Oncotarget. 2017 Jan 17;8(3):4399-4409. doi: 10.18632/oncotarget.12642.

6.

Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood.

Shatzer A, Ali MA, Chavez M, Dowdell K, Lee MJ, Tomita Y, El-Hariry I, Trepel JB, Proia DA, Cohen JI.

Leuk Lymphoma. 2017 Apr;58(4):923-931. doi: 10.1080/10428194.2016.1213823. Epub 2016 Aug 11.

7.

STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.

Heske CM, Mendoza A, Edessa LD, Baumgart JT, Lee S, Trepel J, Proia DA, Neckers L, Helman LJ.

Oncotarget. 2016 Oct 4;7(40):65540-65552. doi: 10.18632/oncotarget.11869.

8.

Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer.

Beck TN, Korobeynikov VA, Kudinov AE, Georgopoulos R, Solanki NR, Andrews-Hoke M, Kistner TM, Pépin D, Donahoe PK, Nicolas E, Einarson MB, Zhou Y, Boumber Y, Proia DA, Serebriiskii IG, Golemis EA.

Cell Rep. 2016 Jul 19;16(3):657-71. doi: 10.1016/j.celrep.2016.06.043. Epub 2016 Jul 7.

9.

A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.

Gaponova AV, Nikonova AS, Deneka A, Kopp MC, Kudinov AE, Skobeleva N, Khazak V, Ogawa LS, Cai KQ, Duncan KE, Duncan JS, Egleston BL, Proia DA, Boumber Y, Golemis EA.

Clin Cancer Res. 2016 Oct 15;22(20):5120-5129. doi: 10.1158/1078-0432.CCR-15-3068. Epub 2016 Jun 7.

10.

Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer.

Mall C, Sckisel GD, Proia DA, Mirsoian A, Grossenbacher SK, Pai CS, Chen M, Monjazeb AM, Kelly K, Blazar BR, Murphy WJ.

Oncoimmunology. 2015 Aug 12;5(2):e1075114. eCollection 2016 Feb.

11.

Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.

Agyeman AS, Jun WJ, Proia DA, Kim CR, Skor MN, Kocherginsky M, Conzen SD.

Horm Cancer. 2016 Apr;7(2):114-26. doi: 10.1007/s12672-016-0251-8. Epub 2016 Feb 8.

12.

Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibition.

Gomez-Casal R, Epperly MW, Wang H, Proia DA, Greenberger JS, Levina V.

Oncotarget. 2015 Dec 29;6(42):44306-22. doi: 10.18632/oncotarget.6248.

13.

Corrigendum: Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.

Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M, Moll UM.

Nature. 2015 Nov 19;527(7578):398. doi: 10.1038/nature15720. Epub 2015 Sep 30. No abstract available.

PMID:
26416737
14.

HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.

Proia DA, Smith DL, Zhang J, Jimenez JP, Sang J, Ogawa LS, Sequeira M, Acquaviva J, He S, Zhang C, Khazak V, Astsaturov I, Inoue T, Tatsuta N, Osman S, Bates RC, Chimmanamada D, Ying W.

Mol Cancer Ther. 2015 Nov;14(11):2422-32. doi: 10.1158/1535-7163.MCT-15-0455. Epub 2015 Aug 13.

15.

Resistance to HSP90 inhibition involving loss of MCL1 addiction.

Busacca S, Law EW, Powley IR, Proia DA, Sequeira M, Le Quesne J, Klabatsa A, Edwards JM, Matchett KB, Luo JL, Pringle JH, El-Tanani M, MacFarlane M, Fennell DA.

Oncogene. 2016 Mar 24;35(12):1483-92. doi: 10.1038/onc.2015.213. Epub 2015 Jun 22.

16.

The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells.

Gomez-Casal R, Bhattacharya C, Epperly MW, Basse PH, Wang H, Wang X, Proia DA, Greenberger JS, Socinski MA, Levina V.

Cancers (Basel). 2015 May 22;7(2):876-907. doi: 10.3390/cancers7020814.

17.

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.

Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M, Moll UM.

Nature. 2015 Jul 16;523(7560):352-6. doi: 10.1038/nature14430. Epub 2015 May 25. Erratum in: Nature. 2015 Nov 19;527(7578):398.

18.

Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy.

Proia DA, Kaufmann GF.

Cancer Immunol Res. 2015 Jun;3(6):583-9. doi: 10.1158/2326-6066.CIR-15-0057. Epub 2015 May 6. Review.

19.

HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.

Whitesell L, Santagata S, Mendillo ML, Lin NU, Proia DA, Lindquist S.

Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):18297-302. doi: 10.1073/pnas.1421323111. Epub 2014 Dec 8.

20.

Inhibiting heat shock protein 90 (HSP90) limits the formation of liver cysts induced by conditional deletion of Pkd1 in mice.

Smithline ZB, Nikonova AS, Hensley HH, Cai KQ, Egleston BL, Proia DA, Seeger-Nukpezah T, Golemis EA.

PLoS One. 2014 Dec 4;9(12):e114403. doi: 10.1371/journal.pone.0114403. eCollection 2014.

21.

Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.

Cercek A, Shia J, Gollub M, Chou JF, Capanu M, Raasch P, Reidy-Lagunes D, Proia DA, Vakiani E, Solit DB, Saltz LB.

Clin Colorectal Cancer. 2014 Dec;13(4):207-12. doi: 10.1016/j.clcc.2014.09.001. Epub 2014 Sep 21.

22.

UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.

Landmann H, Proia DA, He S, Ogawa LS, Kramer F, Beißbarth T, Grade M, Gaedcke J, Ghadimi M, Moll U, Dobbelstein M.

Cell Death Dis. 2014 Sep 11;5:e1411. doi: 10.1038/cddis.2014.378.

23.

The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.

Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, Bates RC, Proia DA.

Target Oncol. 2015 Jun;10(2):235-45. doi: 10.1007/s11523-014-0329-6. Epub 2014 Aug 1.

24.

FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.

Acquaviva J, He S, Zhang C, Jimenez JP, Nagai M, Sang J, Sequeira M, Smith DL, Ogawa LS, Inoue T, Tatsuta N, Knowles MA, Bates RC, Proia DA.

Mol Cancer Res. 2014 Jul;12(7):1042-54. doi: 10.1158/1541-7786.MCR-14-0004. Epub 2014 Apr 30.

25.

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.

He S, Smith DL, Sequeira M, Sang J, Bates RC, Proia DA.

Invest New Drugs. 2014 Aug;32(4):577-86. doi: 10.1007/s10637-014-0095-4. Epub 2014 Apr 1.

26.

Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.

Proia DA, Bates RC.

Cancer Res. 2014 Mar 1;74(5):1294-300. doi: 10.1158/0008-5472.CAN-13-3263. Epub 2014 Feb 20. Review.

27.

mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.

Acquaviva J, He S, Sang J, Smith DL, Sequeira M, Zhang C, Bates RC, Proia DA.

Mol Cancer Res. 2014 May;12(5):703-13. doi: 10.1158/1541-7786.MCR-13-0605. Epub 2014 Feb 19.

28.

WTAP is a novel oncogenic protein in acute myeloid leukemia.

Bansal H, Yihua Q, Iyer SP, Ganapathy S, Proia DA, Penalva LO, Uren PJ, Suresh U, Carew JS, Karnad AB, Weitman S, Tomlinson GE, Rao MK, Kornblau SM, Bansal S.

Leukemia. 2014 May;28(5):1171-4. doi: 10.1038/leu.2014.16. Epub 2014 Jan 13. No abstract available. Erratum in: Leukemia. 2014 Dec;28(12):2427. Proia, D [Corrected to Proia, D A].

29.

Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.

Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, Sang J, Bates RC, Proia DA.

Mol Cancer Ther. 2014 Feb;13(2):353-63. doi: 10.1158/1535-7163.MCT-13-0481. Epub 2014 Jan 7.

30.

Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.

Proia DA, Zhang C, Sequeira M, Jimenez JP, He S, Spector N, Shapiro GI, Tolaney S, Nagai M, Acquaviva J, Smith DL, Sang J, Bates RC, El-Hariry I.

Clin Cancer Res. 2014 Jan 15;20(2):413-24. doi: 10.1158/1078-0432.CCR-13-2166. Epub 2013 Oct 30.

31.

Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.

Liu H, Xiao F, Serebriiskii IG, O'Brien SW, Maglaty MA, Astsaturov I, Litwin S, Martin LP, Proia DA, Golemis EA, Connolly DC.

Clin Cancer Res. 2013 Sep 15;19(18):5053-67. doi: 10.1158/1078-0432.CCR-13-1115. Epub 2013 Jul 30.

32.

Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease.

Seeger-Nukpezah T, Proia DA, Egleston BL, Nikonova AS, Kent T, Cai KQ, Hensley HH, Ying W, Chimmanamada D, Serebriiskii IG, Golemis EA.

Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12786-91. doi: 10.1073/pnas.1301904110. Epub 2013 Jul 15.

33.

Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3.

Nagaraju GP, Park W, Wen J, Mahaseth H, Landry J, Farris AB, Willingham F, Sullivan PS, Proia DA, El-Hariry I, Taliaferro-Smith L, Diaz R, El-Rayes BF.

Angiogenesis. 2013 Oct;16(4):903-17. doi: 10.1007/s10456-013-9364-7. Epub 2013 Jul 10. Erratum in: Angiogenesis. 2013 Oct;16(4):919. Ganji, Purnachandra Nagaraju [corrected to Nagaraju, Ganji Purnachandra].

PMID:
23838996
34.

Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.

Friedland JC, Smith DL, Sang J, Acquaviva J, He S, Zhang C, Proia DA.

Invest New Drugs. 2014 Feb;32(1):14-24. doi: 10.1007/s10637-013-9971-6. Epub 2013 May 18.

35.

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.

Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez JP, Shaw AT, Doebele RC, He S, Bates RC, Camidge DR, Morris SW, El-Hariry I, Proia DA.

Cancer Discov. 2013 Apr;3(4):430-43. doi: 10.1158/2159-8290.CD-12-0440. Epub 2013 Mar 26.

36.

Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.

He S, Zhang C, Shafi AA, Sequeira M, Acquaviva J, Friedland JC, Sang J, Smith DL, Weigel NL, Wada Y, Proia DA.

Int J Oncol. 2013 Jan;42(1):35-43. doi: 10.3892/ijo.2012.1698. Epub 2012 Nov 14.

37.

Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.

Acquaviva J, Smith DL, Sang J, Friedland JC, He S, Sequeira M, Zhang C, Wada Y, Proia DA.

Mol Cancer Ther. 2012 Dec;11(12):2633-43. doi: 10.1158/1535-7163.MCT-12-0615. Epub 2012 Sep 25.

38.

Mitochondrial electron transport is the cellular target of the oncology drug elesclomol.

Blackman RK, Cheung-Ong K, Gebbia M, Proia DA, He S, Kepros J, Jonneaux A, Marchetti P, Kluza J, Rao PE, Wada Y, Giaever G, Nislow C.

PLoS One. 2012;7(1):e29798. doi: 10.1371/journal.pone.0029798. Epub 2012 Jan 11.

39.

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.

Proia DA, Sang J, He S, Smith DL, Sequeira M, Zhang C, Liu Y, Ye S, Zhou D, Blackman RK, Foley KP, Koya K, Wada Y.

Invest New Drugs. 2012 Dec;30(6):2201-9. doi: 10.1007/s10637-011-9790-6. Epub 2012 Jan 10.

40.

Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.

Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J, Ye S, Acquaviva J, Ogawa LS, Wada Y, Barsoum J, Koya K.

Mol Cancer Ther. 2012 Feb;11(2):475-84. doi: 10.1158/1535-7163.MCT-11-0755. Epub 2011 Dec 5.

41.

Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling.

Proia DA, Foley KP, Korbut T, Sang J, Smith D, Bates RC, Liu Y, Rosenberg AF, Zhou D, Koya K, Barsoum J, Blackman RK.

PLoS One. 2011 Apr 14;6(4):e18552. doi: 10.1371/journal.pone.0018552.

42.

Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias.

Bansal H, Bansal S, Rao M, Foley KP, Sang J, Proia DA, Blackman RK, Ying W, Barsoum J, Baer MR, Kelly K, Swords R, Tomlinson GE, Battiwalla M, Giles FJ, Lee KP, Padmanabhan S.

Blood. 2010 Nov 25;116(22):4591-9. doi: 10.1182/blood-2009-10-247239. Epub 2010 Jul 22.

43.

Reconstruction of human mammary tissues in a mouse model.

Proia DA, Kuperwasser C.

Nat Protoc. 2006;1(1):206-14.

PMID:
17406234
44.

Dual roles for the phosphatase PPM1D in regulating progesterone receptor function.

Proia DA, Nannenga BW, Donehower LA, Weigel NL.

J Biol Chem. 2006 Mar 17;281(11):7089-101. Epub 2005 Dec 13.

45.

Stroma: tumor agonist or antagonist.

Proia DA, Kuperwasser C.

Cell Cycle. 2005 Aug;4(8):1022-5. Epub 2005 Aug 7. Review.

PMID:
16082203
46.
47.

Immunochemical characterization of Syrian hamster major histocompatibility complex homologues.

Phillips JT, Streilein JW, Proia DA, Duncan WR.

Adv Exp Med Biol. 1981;134:69-85.

PMID:
6164267

Supplemental Content

Loading ...
Support Center